Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung Bioepis Moves Eylea Biosimilar To Phase III

Multiple Phase III Trials For Aflibercept Candidate In Progress

Executive Summary

Biosimilar competition to Regeneron’s Eylea (aflibercept) eye-disease biologic may emerge as early as 2023, with at least three firms moving candidates to Phase III development following Samsung Bioepis’ study initiation.

You may also be interested in...



COVID-19 Hits Sales Of Biogen Biosimilars Portfolio

Biogen received a bump to biosimilar earnings in the first quarter of this year, but this reversed in Q2 with fewer new patients venturing out to begin treatment on its portfolio of chronic treatment options. Management addressed the numbers, as well as Mylan’s recent victory over its Tecfidera intellectual property in the US.

Samsung Bioepis Eyes US Trastuzumab Potential As It Hits Profitability

In an exclusive interview, the executive vice-president for Samsung Bioepis’ commercial division, Sang-Jin Pak, tells Generics Bulletin there is plenty of opportunity remaining in the crammed US trastuzumab market and explains what an achievement it was for the South Korea-based company to reach profitability only eight years after inception.

Momenta And Mylan Make Strides On Aflibercept

Having largely shelved the firms' global biosimilars collaboration that kicked off early in 2016, Momenta and Mylan are still working towards bringing a biosimilar to the Eylea blockbuster to the US, which currently has a market worth valued at more than $4.5bn.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel